ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,297.10
0.00%
US Tech 100
18,104.40
0.14%
다우존스 지수
39,869.38
0.00%
Bitcoin
66,294.50
1.62%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Alterity Therapeutics Limited (ATHE)

  7. Alterity Therapeutics Limited (ATHE) 뉴스

ATHE

Alterity Therapeutics (ATHE)

Alterity Therapeutics Limited
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:ATHE
일자시간출처헤드라인심볼기업
2024/05/0820:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third ReviewNASDAQ:ATHEAlterity Therapeutics Limited
2024/04/3020:25GlobeNewswire Inc.Appendix 4C – Q3 FY24 Quarterly Cash Flow ReportNASDAQ:ATHEAlterity Therapeutics Limited
2024/04/2920:25GlobeNewswire Inc.Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s AtaxiaNASDAQ:ATHEAlterity Therapeutics Limited
2024/04/1720:25GlobeNewswire Inc.Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
2024/04/1020:25GlobeNewswire Inc.Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024NASDAQ:ATHEAlterity Therapeutics Limited
2024/03/2623:25GlobeNewswire Inc.Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive RefundNASDAQ:ATHEAlterity Therapeutics Limited
2024/02/2100:25GlobeNewswire Inc.Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual MeetingNASDAQ:ATHEAlterity Therapeutics Limited
2024/02/1607:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/02/1607:28Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ATHEAlterity Therapeutics Limited
2024/02/0621:25GlobeNewswire Inc.Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second ReviewNASDAQ:ATHEAlterity Therapeutics Limited
2024/01/3122:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/2921:24GlobeNewswire Inc.Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This WeekNASDAQ:ATHEAlterity Therapeutics Limited
2024/01/2221:25GlobeNewswire Inc.Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming MilestonesNASDAQ:ATHEAlterity Therapeutics Limited
2024/01/2220:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/1822:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/1207:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/1207:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/1020:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0822:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0822:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0822:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0822:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0520:27Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0520:24Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0222:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0222:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2024/01/0222:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2023/12/2922:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2023/12/2922:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
2023/12/2122:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ATHEAlterity Therapeutics Limited
 검색 관련기사 보기:NASDAQ:ATHE

최근 히스토리

FX
USDGBP
US Dollar vs Sterling
CCOM
US500
US 500
PM
XAUUSD
Gold vs US Dollar
USOTC
RHHBY
Roche (QX)
AMEX
XLV
Health Care Select Sector
NASDAQ
AAPL
Apple
NYSE
KO
Coca Cola
COIN
SOLUSD
Solana
AMEX
XLE
Energy Select Sector SPDR
NYSE
MRK
Merck
NYSE
MCD
McDonalds
AMEX
SPY
SPDR S&P 500
NASDAQ
GOOGL
Alphabet
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유